Columbia Cornerstone Growth Fund Q4 2025 Quarterly Portfolio Recap

U.S. equities rose 2.41% in Q4 on the Russell 1000, with leadership broadening away from mega-cap tech and value stocks outperforming growth. Eli Lilly was a notable outperformer, delivering strong earnings driven by its dominant obesity treatments, reinforcing the market rotation into healthcare and value-oriented names.

Analysis

Healthcare: the structural demand shock from broad adoption of next‑gen metabolic/obesity therapeutics cascades beyond the originator drugmakers into a handful of capacity‑constrained CMOs, peptide API suppliers, and specialty distribution channels. These suppliers can convert lumpy volume into outsized margin expansion over 6–24 months if capacity remains tight; conversely, rapid capex responses or generic/biosimilar entrants would compress multiples quickly because revenue is highly concentrated.

Market Technicals & Flows: a rotation away from concentration risk tends to be flow‑amplified—reconstitution, factor‑tilts, and passive ETF reweights can drive several percentage points of relative performance for mid/small caps in a 30–90 day window. That same dynamic creates vulnerability: a single macro repricing (hawkish Fed, recession scare) can reverse flows violently, producing mean reversion in value vs growth within weeks.

Risk & Catalysts: key catalysts to watch are payer policy (PBM step therapy and Medicare listing) over 3–12 months, CMO capacity announcements and backlog visibility over 6–18 months, and macro liquidity/Fed signals on a 1–3 month horizon. Tail risks include expedited generics/biosimilars or a political push to cap pricing (fast, binary, 12–36 months), and an earnings cycle where cyclicals miss current year guidance causing a sharp rotation back into cash‑flow visible tech.

Contrarian: consensus treats the rotation and therapeutic adoption as durable; it may be partially overdone. Tech still has idiosyncratic AI revenue optionality and more stable cash flows than many value names priced for recovery—position sizing should reflect asymmetric policy/regulatory risk in healthcare and the high likelihood of short‑term reversals in flow‑driven rallies.

Key Decisions for Investors

• Pair trade (30–90 days): Long KRE (regional bank ETF) 1.0% portfolio weight vs Short XLK 0.6% — target 15–25% relative outperformance, stop the pair if XLK outperforms KRE by 8% (risk: reacceleration of tech earnings or a short‑term yield shock).
• Healthcare supply‑chain long (6–18 months): Buy CTLT (Catalent) 1.0% weight — thesis: peptide/API capacity tightness => revenue re‑rating; target +30–50% and set hard stop at −20% (risk: rapid capex expansion or contract deprioritization by major drugmakers).
• Convex biotech hedge (12 months): Buy a call spread on LLY (e.g., buy 12‑month 25–30 delta calls and sell 60–70 delta calls) sized as 0.5% portfolio exposure — aims for 2.5x+ if pricing/payer outcomes surprise positively, max loss = premium paid (risk: regulatory/payer clampdown).
• Short speculation (6–12 months): Short select consumer/clinic names exposed to overhyped obesity spillover (example: WW) at modest size 0.5% — target −30–50% if utilization normalizes or reimbursement tightens, stop at +20% adverse move (risk: durable consumer demand or unexpected M&A bid).